“In my view, the sweet spot for amyloid-lowering trials is mild Alzheimer’s disease, ” Dr. Selkoe said.

Selkoe还说：“在我看来，轻度老年痴呆症患者是降低淀粉样蛋白试验的最佳对象。”

youdao

Selkoe, D. J. , and D. Schenk. "Alzheimer's Disease: Molecular Understanding predicts Amyloid-based Therapeutics. " Annu Rev Pharmacol Toxicol. 43(2003): 545-84.

阿兹海莫症：以分子生物学领域的了解预测以类淀粉胜肽为基础的治疗〉《药理学与毒物学研究回顾杂志》 43（2003）： 545-84。

youdao

These days Lansbury, Selkoe and other proponents of the cluster theory are suddenly in the mainstream.

FORBES: Health

It does so, Selkoe's lab figured out, by boosting the secretion of amyloid fragments by brain cells.

FORBES: Executive Health

Selkoe teamed up with venture capitalists in 1986 to found Athena Neurosciences, now part of Elan Corp. of Dublin, Ireland.

FORBES: Attacking Alzheimer's